Investing in China's Biotech: Opportunities and Risks

The panel discusses the rapid growth of Chinese biotech, driven by overseas returnees and government support. Companies like Nanjing Legend are making significant strides, surprising many with their progress. The discussion covers investment challenges, the shift to biologic drugs, and the potential market opportunities in China. Despite pricing challenges, the volume of patients offers a unique advantage. The future looks promising, with Chinese companies aiming for global impact. The panel also explores the implications of biotech companies listing on stock exchanges, highlighting the need for careful evaluation.

What new insight or understanding did you gain from this video?